A Du Bois

Summary

Affiliation: Dr Horst Schmidt Klinik
Country: Germany

Publications

  1. ncbi request reprint A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
    Andreas du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Kliniken, Wiesbaden, Germany
    J Natl Cancer Inst 95:1320-9. 2003
  2. pmc A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours
    A Du Bois
    Department of Gynaecology and Gynaecologic Oncology, HSK, Dr Horst Schmidt Klinik, Ludwig Erhard Str 100, Wiesbaden D 65199, Germany
    Br J Cancer 94:79-84. 2006
  3. ncbi request reprint Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)
    A Du Bois
    HSK, Dr Horst Schmidt Klinik, Department of Gynecology and Gynecologic Oncology, Wiesbaden, Germany
    Ann Oncol 17:93-6. 2006
  4. ncbi request reprint 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
    A Du Bois
    Department of Gynecology and Gynecologic Oncology, Wiesbaden, Germany
    Ann Oncol 16:viii7-viii12. 2005
  5. ncbi request reprint A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)
    A Du Bois
    Department of Gynecology and Gynecologic Oncology, and AGO Study Secretary, Dr Horst Schmidt Klinik Wiesbaden HSK, Ludwig Erhard Str 100, D 65199 Wiesbaden, Germany
    Gynecol Oncol 96:444-51. 2005
  6. ncbi request reprint [The Quality Assurance Program of the AGO Organkommission OVAR (QS-OVAR): Pattern of Care and Reality in Germany 2001]
    A Du Bois
    Klinik für Gynakologie and Gynäkologische Onkologie, HSK Wiesbaden, Germany
    Zentralbl Gynakol 127:9-17. 2005
  7. ncbi request reprint [Impact of center characteristics on outcome in ovarian cancer in Germany]
    A Du Bois
    Klinik für Gynakologie and Gynäkologische Onkologie, HSK Wiesbaden, Germany
    Zentralbl Gynakol 127:18-30. 2005
  8. ncbi request reprint Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer
    A Du Bois
    Dept Gynaecology and Gynaecologic Oncology, HSK Wiesbaden, Germany
    Int J Gynecol Cancer 15:183-91. 2005
  9. ncbi request reprint Future options for first-line therapy of advanced ovarian cancer
    A Du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik HSK, Wiesbaden, Germany
    Int J Gynecol Cancer 15:42-50. 2005
  10. ncbi request reprint [First-line therapy in ovarian cancer]
    A Du Bois
    Klinik für Gynakologie and Gynäkologische Onkologie, Dr Horst Schmidt Kliniken Wiesbaden
    Zentralbl Gynakol 126:312-4. 2004

Detail Information

Publications49

  1. ncbi request reprint A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
    Andreas du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Kliniken, Wiesbaden, Germany
    J Natl Cancer Inst 95:1320-9. 2003
    ..Therefore, we performed a randomized, phase III non-inferiority trial comparing paclitaxel plus cisplatin (PT) with paclitaxel plus carboplatin (TC) in patients with advanced ovarian cancer...
  2. pmc A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours
    A Du Bois
    Department of Gynaecology and Gynaecologic Oncology, HSK, Dr Horst Schmidt Klinik, Ludwig Erhard Str 100, Wiesbaden D 65199, Germany
    Br J Cancer 94:79-84. 2006
    ..8+/-7.7 h, respectively. The maximum tolerated and recommended phase II dose for BMS-188797 was 110 mg m(-2) (1-h infusion, every 3 weeks) combined with cisplatin 75 mg m(-2)...
  3. ncbi request reprint Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)
    A Du Bois
    HSK, Dr Horst Schmidt Klinik, Department of Gynecology and Gynecologic Oncology, Wiesbaden, Germany
    Ann Oncol 17:93-6. 2006
    ..Based on evidence that combination platinum-containing regimens offer superior efficacy versus single-agent regimens, we conducted this study to determine the maximum tolerated dose (MTD) of PLD in combination with carboplatin...
  4. ncbi request reprint 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
    A Du Bois
    Department of Gynecology and Gynecologic Oncology, Wiesbaden, Germany
    Ann Oncol 16:viii7-viii12. 2005
  5. ncbi request reprint A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)
    A Du Bois
    Department of Gynecology and Gynecologic Oncology, and AGO Study Secretary, Dr Horst Schmidt Klinik Wiesbaden HSK, Ludwig Erhard Str 100, D 65199 Wiesbaden, Germany
    Gynecol Oncol 96:444-51. 2005
    ..A multicenter, nonrandomized, phase II study was initiated to evaluate the tolerability, toxicity, and activity of paclitaxel, carboplatin, and gemcitabine combination in previously untreated ovarian cancer...
  6. ncbi request reprint [The Quality Assurance Program of the AGO Organkommission OVAR (QS-OVAR): Pattern of Care and Reality in Germany 2001]
    A Du Bois
    Klinik für Gynakologie and Gynäkologische Onkologie, HSK Wiesbaden, Germany
    Zentralbl Gynakol 127:9-17. 2005
    ..To evaluate pattern and quality of care for ovarian cancer in Germany and analyze adherence to treatment guidelines as well as prognostic factors for survival...
  7. ncbi request reprint [Impact of center characteristics on outcome in ovarian cancer in Germany]
    A Du Bois
    Klinik für Gynakologie and Gynäkologische Onkologie, HSK Wiesbaden, Germany
    Zentralbl Gynakol 127:18-30. 2005
    ..To evaluate the relationship between hospital characteristics and quality of care and outcome in ovarian cancer in Germany...
  8. ncbi request reprint Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer
    A Du Bois
    Dept Gynaecology and Gynaecologic Oncology, HSK Wiesbaden, Germany
    Int J Gynecol Cancer 15:183-91. 2005
    ..Selecting an institution that participates in cooperative trials might be an option for individual patients seizing the chance for better quality of care even when individual factors might hamper enrollment in a study...
  9. ncbi request reprint Future options for first-line therapy of advanced ovarian cancer
    A Du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik HSK, Wiesbaden, Germany
    Int J Gynecol Cancer 15:42-50. 2005
    ..Data on the addition of gemcitabine are eagerly awaited from two phase III trials...
  10. ncbi request reprint [First-line therapy in ovarian cancer]
    A Du Bois
    Klinik für Gynakologie and Gynäkologische Onkologie, Dr Horst Schmidt Kliniken Wiesbaden
    Zentralbl Gynakol 126:312-4. 2004
    ..It is essential for the improvement of the patients' situation to transfer these new developments already implemented into national and international standards and guidelines to clinical practice...
  11. ncbi request reprint [Ovarian cancer -- can peritoneal therapy be regarded as new standard?]
    A Du Bois
    Klinik für Gynäkologie und gynäkologische Onkologie, HSK Dr Horst Schmidt Klinik, Wiesbaden
    Zentralbl Gynakol 128:202-6. 2006
    ..therapy. In order to change the current standard, it would be necessary to base the analysis on an ITT-population, provide details about second-line therapy, rule out bias regarding second-line therapy and to develop less toxic regimens...
  12. ncbi request reprint Improving first-line therapy of advanced ovarian cancer - the AGO Ovarian Cancer Study Group perspective
    A Du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Kliniken, Wiesbaden, Germany
    Int J Gynecol Cancer 13:169-71. 2003
    ....
  13. ncbi request reprint Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-U
    A Du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Ludwig Erhard Str 100, 65185 Wiesbaden, Germany
    Gynecol Oncol 107:518-25. 2007
    ..A multicenter non-randomized phase II study was initiated to evaluate tolerability and efficacy of pegylated liposomal doxorubicin (PLD) in combination with carboplatin in gynecologic malignancies...
  14. ncbi request reprint Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study G
    Andreas du Bois
    Department of Gynecology and Gynecologic Oncology, HSK Dr Horst Schmidt Klinik Wiesbaden, Wiesbaden, Germany
    J Clin Oncol 24:1127-35. 2006
    ..One attempt to improve results could be the addition of non-cross-resistant drugs to platinum-paclitaxel combination regimens. Anthracyclines were among the candidates for incorporation as a third drug into first-line regimens...
  15. ncbi request reprint Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer
    Bois A du
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Kliniken Wiesbaden, Germany
    Ann Oncol 13:251-7. 2002
    ..Here we evaluate whether a second-line chemotherapy can offer any benefit compared with a less toxic hormonal treatment...
  16. ncbi request reprint Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group
    A Du Bois
    Department of Gynecology, Dr Horst Schmidt Kliniken Wiesbaden, Germany
    Ann Oncol 12:1115-20. 2001
    ..Carboplatin reinduction is a broadly adopted regimen in patients with recurrences occurring six months or later after first-line treatment. Gemcitabine is among the candidates as combination partner in second-line regimens...
  17. ncbi request reprint Treatment of advanced ovarian cancer
    A Du Bois
    Gynäkologie and Gynäkolgische Onkologie, Dr Horst Schmidt Klinken, Ludwig Erhard Strasse 100, D 65199, Wiesbaden, Germany
    Eur J Cancer 37:S1-7. 2001
    ..However, response duration rarely exceeds 12 months and increased efforts are needed in this area of chemotherapy...
  18. ncbi request reprint Non-enrolment of ovarian cancer patients in clinical trials: reasons and background
    P Harter
    HSK, Dr Horst Schmidt Klinik Wiesbaden, Department of Gynaecology and Gynaecological Oncology, Wiesbaden, Germany
    Ann Oncol 16:1801-5. 2005
    ..Some retrospective analyses have suggested that participation in clinical trials is associated with better outcome. However, it is not clear to what extent selection bias contributes to this observation...
  19. doi request reprint A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
    A Du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik HSK, Wiesbaden, Germany
    Ann Oncol 21:370-5. 2010
    ....
  20. doi request reprint Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival
    F Heitz
    Department of Gynecology and Gynecological Oncology, EUSOMA Breast Unit, HSK, Dr Horst Schmidt Kliniken, Wiesbaden, Germany
    Ann Oncol 22:1571-81. 2011
    ..Survival of patients suffering from cerebral metastases (CM) is limited. Identification of patients with a high risk for CM is warranted to adjust follow-up care and to evaluate preventive strategies...
  21. ncbi request reprint [Anthracyclines in therapy of ovarian carcinoma: a systematic review of primary and 2nd-line therapy after platinum]
    A Du Bois
    Klinik für Gynakologie and Gynäkologische Onkologie, Dr Horst Schmidt Kliniken Wiesbaden
    Zentralbl Gynakol 122:255-67. 2000
    ..No final conclusions can be drawn. There is a need for developing effective 2nd-line therapies for patients failing platinum and paclitaxel combination regimens. Among others, anthracyclines should be evaluated in this clinical setting...
  22. ncbi request reprint Ovarian cancer--can intraperitoneal therapy be regarded as new standard in Germany?
    A Du Bois
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik HSK Wiesbaden, Germany
    Int J Gynecol Cancer 16:1756-60. 2006
    ....
  23. doi request reprint Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery
    J P Grabowski
    Dept of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Ludwig Erhard Str 100, 65199 Wiesbaden, Germany
    Surg Oncol 21:31-5. 2012
    ..The purpose of our study was to evaluate re-operation in a tertiary gynecologic oncology unit after primary operation for presumably ovarian cancer FIGO I-IIIA in general gynecology departments...
  24. doi request reprint Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials
    S Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Eur J Cancer 49:142-9. 2013
    ..The impact of the time interval between surgery and initiation of chemotherapy for clinical outcome has not been clarified yet...
  25. ncbi request reprint Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer
    S Kommoss
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Wiesbaden, Germany
    Ann Surg Oncol 17:279-86. 2010
    ..Complete tumor resection may require extended surgical procedures. This paper reports on the prognostic impact of extensive surgery and surgical morbidity in patients with advanced-stage ovarian carcinoma...
  26. doi request reprint Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis
    P Harter
    Department of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Wiesbaden, Germany
    Ann Surg Oncol 16:1324-30. 2009
    ..Peritoneal carcinomatosis has been reported to be either a negative predictor for resectability or a negative prognostic factor, or both. The role of peritoneal carcinomatosis in a multicenter trial was investigated...
  27. ncbi request reprint Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity
    M J Kandel
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Kliniken, Wiesbaden, Germany
    Int J Gynecol Cancer 15:780-4. 2005
    ..However, close monitoring of neurotoxicity is necessary, particularly in patients with residual neurotoxicity due to prior platinum- and taxane-containing chemotherapy...
  28. pmc Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaek
    S Kommoss
    Dr Horst Schmidt Klinik HSK Wiesbaden, Department of Gynecology and Gynecologic Oncology, Ludwig Erhard Str 100, Wiesbaden 65199, Germany
    Br J Cancer 96:306-13. 2007
    ..High pRb expression is a significant prognosticator in optimally debulked patients and may hold potential for subgroup stratification in postoperative treatment...
  29. ncbi request reprint Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer
    P Harter
    Department of Gynecology, Dr Horst Schmidt Klinik HSK, Wiesbaden, Germany
    Int J Gynecol Cancer 17:1238-44. 2007
    ..Systematic pelvic and para-aortic lymphadenectomy remains part of staging in EOC. Patients with EOC should be offered the opportunity to receive state-of-the-art treatment including surgery...
  30. ncbi request reprint The role of surgery in advanced and recurrent ovarian cancer
    A Du Bois
    HSK, Dr Horst Schmidt Klinik Wiesbaden, Department of Gynaecology and Gynaecologic Oncology, Wiesbaden, Germany
    Ann Oncol 17:x235-40. 2006
  31. ncbi request reprint Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer
    M J Piccart
    EORTC Gynecological Cancer Cooperative Group, Brussels, Belgium
    Int J Gynecol Cancer 13:144-8. 2003
    ....
  32. pmc A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
    P A Vasey
    CR UK Clinical Trials Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow, Scotland G11 6NT, UK
    Br J Cancer 98:1774-80. 2008
    ..Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy...
  33. ncbi request reprint Caelyx: treatment for relapsing ovarian cancer
    S R Johnston
    Royal Marsden Hospital, London SW3 6JJ
    Hosp Med 62:611-6. 2001
    ..Caelyx is a new treatment using long-circulating liposomes to target delivery of doxorubicin to the tumour. This article reviews the treatment of ovarian cancer and looks at the place of Caelyx as a new second-line treatment option...
  34. ncbi request reprint Participation of patients with gynecological cancer in phase I clinical trials: two years experience in a major cancer center
    F Legge
    Gynecologic Oncology Unit, Catholic University of Campobasso, Italy Gynecologic Oncology Unit, Catholic University of Rome, Italy
    Gynecol Oncol 104:551-6. 2007
    ..The possible clinical benefit to patients resulting from the participation in these trials has been also investigated...
  35. pmc A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
    C N Krasner
    Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA
    Br J Cancer 97:1618-24. 2007
    ..Trabectedin is an active treatment, with documented responses in patients with platinum sensitive advanced relapsed ovarian cancer, and has a manageable toxicity profile...
  36. pmc A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
    M Harries
    Section of Medicine, Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, London, UK
    Br J Cancer 91:627-32. 2004
    ..However, the observation of pulmonary toxicity, potentially a feature of the weekly taxane-gemcitabine regimen, was of some concern. Alternative schedules, including 3-weekly taxanes, are currently being evaluated...
  37. ncbi request reprint Reversing resistance to targeted therapy
    L Vidal
    Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
    J Chemother 16:7-12. 2004
    ....
  38. pmc Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial
    C Rothermundt
    The Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 94:74-8. 2006
    ..The combination of epirubicin, carboplatin and capecitabine showed good activity but caused excessive toxicity. A phase-II trial using carboplatin and capecitabine is underway...
  39. pmc Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours
    M Harries
    The CRUK Department of Medical Oncology, Royal Marsden Hospital Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 91:1651-5. 2004
    ..Further studies with Carboplatin AUC 5 and DHA-paclitaxel 880 mg m(-2), given every 28 days, are warranted in chemo-naive patients...
  40. pmc SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer
    P A Vasey
    CR UK Clinical Trials Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, UK
    Br J Cancer 94:62-8. 2006
    ..Larger phase III studies are required to test these combinations...
  41. pmc Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours
    M J A de Jonge
    Department of Medical Oncology, Erasmus Medical Center Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Br J Cancer 91:1459-65. 2004
    ..In this study, the DLTs of XR11576 were diarrhoea and fatigue. The recommended dose for phase II studies of XR11576 is 120 mg administered orally, on days 1-5 every 21 days. Alternative regimens are currently being explored...
  42. pmc A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
    C Benson
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 96:29-37. 2007
    ..No objective tumour responses were noted, but disease stabilisation was recorded in eight patients; this lasted for a total of six courses (18 weeks) in a patient with ovarian cancer...
  43. ncbi request reprint 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration
    G Stuart
    NCIC CTG, Canada
    Ann Oncol 16:viii36-viii38. 2005
  44. pmc Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
    H T Arkenau
    Royal Marsden Hospital, Institute of Cancer Research, Downs Road, Sutton SM2 5PT, UK
    Br J Cancer 98:1029-33. 2008
    ..Risk scoring based on objective clinical parameters indicated that patients with a high score had a significantly shorter OS, and this may help in the process of patient selection for phase I trial entry...
  45. pmc Clinical anticancer drug development: targeting the cyclin-dependent kinases
    C Benson
    Section of Medicine and Cancer Research UK Centre for Cancer Therapeutics, Institute for Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 92:7-12. 2005
    ..The critical nature of these proteins in cell cycling raises hope that targeting them may result in selective cytotoxicity and valuable anticancer activity...
  46. ncbi request reprint New paradigms in the treatment of breast and colorectal cancer--an introduction
    S Kaye
    Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
    Eur J Cancer 38:1-2. 2002
  47. ncbi request reprint Use of intravenous cyclophosphamide in the prevention of corneal melt: justified or not?
    A R Clewes
    Rheumatology (Oxford) 44:257-8. 2005
  48. pmc Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
    T Eisen
    Royal Marsden Hospital, Downs Road, Surrey SMT 5PT, UK
    Br J Cancer 95:581-6. 2006
    ..i.d.). Ongoing trials in advanced melanoma are evaluating sorafenib combination therapies...
  49. ncbi request reprint Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens
    T Thigpen
    Department of Medicine, Division of Oncology, University of Mississippi Medical Center, Jackson 39216, USA
    Ann Oncol 16:viii13-viii19. 2005